抑制固醇调节元件结合蛋白通路通过抑制小鼠炎症反应抑制肝细胞癌
研究在小鼠中通过基因或药物(白桦脂醇)抑制固醇调节元件结合蛋白(SREBP)通路,发现可显著减少二乙基亚硝胺诱导的肝细胞癌进展,并下调促肿瘤细胞因子IL-6、肿瘤坏死因子α和IL-1β。结论认为抑制SREBP通路可预防肝细胞癌,提示一种新的代谢策略。
要点
- 基因或药物抑制SREBP通路可减少二乙基亚硝胺诱导的小鼠肝细胞癌进展。
- 抑制SREBP通路下调促肿瘤细胞因子IL-6、肿瘤坏死因子α和IL-1β。
- 作者认为抑制SREBP通路可预防肝细胞癌,并提示新的代谢策略。
核心结论
- 抑制SREBP通路以减少从头脂质合成可预防肝细胞癌。
研究设计与样本
- 在小鼠中通过肝细胞敲除78-kDa细胞表面糖蛋白或SREBP裂解激活蛋白,以及给予化合物白桦脂醇来阻断SREBP通路。
主要发现
- 基因或药物抑制SREBP通路均显著减少二乙基亚硝胺诱导的肝细胞癌进展。
- 抑制SREBP通路下调促肿瘤细胞因子IL-6、肿瘤坏死因子α和IL-1β。
临床怎么用
- 作者认为抑制SREBP通路可预防肝细胞癌,并提示一种新的代谢策略来控制肝癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Obesity is a critical risk factor for hepatocellular carcinoma (HCC). However, it remains unknown whether inhibition of de novo lipid biosynthesis can suppress HCC. In this study, we blocked the sterol regulatory element-binding protein (SREBP) pathway, one of the key determinants of lipid homeostasis, by ablating 78-kDa cell-surface glycoprotein or SREBP cleavage-activating protein in hepatocytes, as well as by administering a chemical compound called betulin. We found that either genetically or pharmacologically inhibiting the SREBP pathway dramatically reduced diethylnitrosamine-induced HCC progression by down-regulating tumor-promoting cytokines, including interleukin (IL)-6, tumor necrosis factor alpha, and IL-1β. CONCLUSION: Inhibition of de novo lipid biosynthesis by suppressing the SREBP pathway prevents HCC. This study identifies a previously underappreciated role of the SREBP pathway in HCC and suggests a novel metabolic strategy to control liver cancer. (Hepatology 2017;65:1936-1947).
引用
- Li N, Zhou ZS, Shen Y, et al. Inhibition of the sterol regulatory element-binding protein pathway suppresses hepatocellular carcinoma by repressing inflammation in mice. Hepatology. 2017. PMID: 28027595. doi:10.1002/hep.29018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。